U.S. District Judge Matthew Kennelly dissed almost all the arguments AbbVie and Abbott Laboratories made for a summary judgment before the first of seven bellwether trials involving cardiovascular risks with the testosterone replacement treatment AndroGel begins, Law360 reported. The drug companies face more than 7,000 lawsuits in a sprawling multidistrict litigation (MDL) involving several different manufacturers of testosterone replacement therapies. As the maker of the top selling AndroGel, AbbVie will sit in the hot seat for all seven of the selected bellwethers. The first trial is set to begin in June. Plaintiffs suing AbbVie and other testosterone treatment manufacturers allege ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.